GLP-2 Peptide 30 MG

Description

DESCRIPTION

Tirzepatide is a synthetic peptide investigated as a dual GLP-1 and GIP receptor agonist. It is studied in research models for receptor binding, downstream signaling, and comparative pharmacology within the incretin receptor family.

RESEARCH AREAS

• Dual receptor activity — studied for simultaneous binding at GLP-1 and GIP receptors in cell-based assays.
• Signaling pathway research — investigated for cAMP activation downstream of receptor engagement.
• Metabolic model studies — explored in rodent models of glucose homeostasis.
• Comparative receptor profiling — characterized in published literature alongside single-receptor GLP-1 compounds.

WHAT RESEARCHERS LOOK AT

• Mechanism: dual GLP-1 and GIP receptor agonism.
• Receptor binding affinity and pathway activation profiles.
• Comparative characterization against single-receptor GLP compounds.
• Applications in incretin and metabolic pathway research.

QUICK SPECS

• Form: Lyophilized peptide
• Net per vial: 30 mg
• Purity: ≥99% (HPLC)
• Identity: MS-verified (per COA)
• Storage: 2–8 °C, protect from light

IDENTITY BASICS

• Type: Dual GIP/GLP-1 receptor agonist
• Formula / M.W.: Peptide analog (varies by formulation)

SELECTED RESEARCH

• PubChem entry — chemical identity:
  
  https://pubchem.ncbi.nlm.nih.gov/compound/137329144
  
• Receptor pharmacology and pathway research (2021):
  
  https://pubmed.ncbi.nlm.nih.gov/34170647/
  
• Pharmacokinetic characterization (NEJM, 2021):
  
  https://pubmed.ncbi.nlm.nih.gov/34170646/
  
• Pharmacology and biochemistry profile:
  
  https://pubmed.ncbi.nlm.nih.gov/36718633/
  

DISCLAIMER

• This product is intended for laboratory research use only.

• Not for human or veterinary use.

• Not approved for diagnostic, therapeutic, or medical applications.

• Handle using appropriate laboratory safety procedures and personal protective equipment.